各MTAの最後の条文は以下の通りです。

* **UK Biobank (UKBB):** Clause 15.3, which states that the provisions of Clause 15 shall not affect any other right which any party may have to terminate this MTA.
* **European Genome-phenome Archive (EGA):** Clause 19 states that the agreement and any dispute arising from it shall be governed by the laws of England and Wales and be subject to the exclusive jurisdiction of the English courts.
* **National Institutes of Health (NIH):** Clause 10, which covers miscellaneous contract boilerplate, such as clauses related to assignment, notices, survival, counterparts, and force majeure.

***

以下は、UKBBの条文と、内容的に対応するEGAおよびNIHの条文の比較です。

### 13. Notices
### 13.1 Notices required under this MTA shall be in writing and shall be: 13.1.1 sent by email to the addresses set out below; or 13.1.2 (in the event of failure to deliver an email) by post to the registered address of UK Biobank or the Applicant.
* 対応するEGAの条文はありません
* 対応するNIHの条文はありません

### 13.2 Any notice shall be deemed to be received: 13.2.1 if sent by email, upon receipt at the recipient’s email server, (or, if this time falls outside business hours in the place of receipt, when business hours resume); or 13.2.2 if sent by post, on the date of delivery if a business day in the place of receipt (or, if not a business day, on the first business day thereafter).
* 対応するEGAの条文はありません
* 対応するNIHの条文はありません

### 13.3 Notices to UK Biobank shall be sent to the access team at access@ukbiobank.ac.uk. Notices to the Applicant shall be sent by email to the relevant Applicant and the Applicant PI.
* 対応するEGAの条文はありません
* 対応するNIHの条文はありません

***

### 14. Affiliates, assignment and sub-contracting
### 14.1 The rights granted to the Applicant under this MTA for the Approved Research Project include the Affiliates of the Applicant, subject to the Applicant: 14.1.1 providing updated details of each Affiliate in the Annual Project Report submitted to UK Biobank on an annual basis in accordance with clause 7.1 of the MTA; 14.1.2 remaining fully liable and responsible to UK Biobank for all acts, defaults and omissions of each of its Affiliates as if they were the Applicant’s own; and 14.1.3 ensuring that each of its Affiliates comply with the terms and conditions of this MTA.
* 対応するEGAの条文はありません
* 対応するNIHの条文はありません

### 14.2 Neither UK Biobank nor the Applicant shall be entitled to assign this MTA or any of its rights or obligations hereunder without first having received the written approval of the other party, such approval not to be unreasonably withheld or delayed.
* 対応するEGAの条文はありません
* 対応するNIHの条文はありません

### 14.3 Other than in the circumstances set out in clause 14.5, the Applicant shall not sub-contract the performance of any of its obligations under the MTA or any part thereof without having first obtained the prior written consent of UK Biobank, such consent not to be unreasonably withheld.
* 対応するEGAの条文はありません
* 対応するNIHの条文はありません

### 14.4 In the event that consent is granted under clause 14.3, the relevant Applicant shall be responsible for the acts, defaults and omissions of its sub-contractors as if they were the Applicant’s own, and any consent given shall not relieve such relevant Applicant of any of its obligations under this MTA.
* 対応するEGAの条文はありません
* 対応するNIHの条文はありません

### 14.5 UK Biobank acknowledges and agrees that the Applicant may subcontract to third party processors to process the Materials strictly for the Permitted Purpose and only in relation to discrete elements of data computation and analysis (such processors being, "Third-Party Processors"). The Applicant must comply with, and only engage Third-Party Processors strictly in accordance with the terms set out in clauses 14.6 to 14.10 inclusive.
* 対応するEGAの条文はありません
* 対応するNIHの条文はありません

### 14.6 The Applicant warrants that the Third-Party Processor is not a Collaborator and shall only be engaged for the purposes of discrete elements of data computation and analysis in relation to the Permitted Purpose (the "Processor Task").
* 対応するEGAの条文はありません
* 対応するNIHの条文はありません

### 14.7 Prior to engaging a Third-Party Processor, the Applicant shall conduct and document the following assessment: 14.7.1 whether the Third-Party Processor is necessary for the progress of the research aims of the Approved Research Project; 14.7.2 whether the Third-Party Processor is a suitable recipient for the data in terms of both its provenance on past data security and past data usage / activities (for example Cambridge Analytica would not qualify); and 14.7.3 whether the Third-Party Processor is able to provide sufficient assurance(s) that it shall process the Materials in a manner that will meet the requirements of Data Protection Legislation.
* 対応するEGAの条文はありません
* 対応するNIHの条文はありません

### 14.8 The Applicant shall: 14.8.1 remain fully responsible to UK Biobank for all acts, defaults and omissions of the Third-Party Processor as if they were the Applicant's own; 14.8.2 provide only such Materials to the Third-Party Processor as is strictly necessary for the Third-Party Processor to perform the Processor Task; 14.8.3 provide details of each Third-Party Processor and the Processor Task in the Annual Project Report submitted to UK Biobank on an annual basis in accordance with clause 7.1 of the MTA; and 14.8.4 only engage the Third-Party Processor on the basis that a written agreement with the Third-Party Processor is executed prior to any data transfer or processing of Materials taking place. Such agreement must include inter alia: (a) a clear definition and scope of the Processor Task, including an agreement only to process the data in accordance with the Applicant’s documented instructions; (b) to authorise the Third-Party Processor only to undertake the Processor Task and not to perform any other act, unless expressly authorised to do so; (c) to store, process and use the Materials to the security standards set out in the MTA (as a minimum) and implements appropriate technical and organisational security measures to protect the Materials against a Data Security Incident; (d) to delete (or render permanently inaccessible) the Materials (and any data generated as a result of the Processor Task) once the Processor Task has been completed; (e) to confirm that the Third-Party Processor has no rights (directly or indirectly) in either any Materials (or data derived therefrom) or from anything which the Applicant has created or done as part of the Approved Research Project (which is covered by the MTA between UK Biobank and the Applicant); (f) to confirm that the Third-Party Processor is bound by the provisions which are equivalent to the relevant provisions in the MTA, including, but not limited to: a) not to transfer the Materials (or data derived therefrom) to any third party and b) not to make any attempt to re-identify any Participant; (g) that the Third-Party Processor provides sufficient assurance(s) that it shall process the Materials in a manner that will meet the requirement of Data Protection Legislation; and (h) that the Applicant has an unfettered unilateral right to terminate its agreement with the Third-Party Processor immediately if a material problem arises (including a breach by the Third-Party Processor of any of the above provisions).
* 対応するEGAの条文はありません
* 対応するNIHの条文はありません

### 14.9 The Applicant must keep the activities of the Third-Party Processor under reasonable review in order to ensure compliance with clauses 14.5 to 14.10 inclusive.
* 対応するEGAの条文はありません
* 対応するNIHの条文はありません

### 14.10 In the event that UK Biobank raises any concern regarding the identity of the Third-Party Processor or the activities of a Third-Party Processor, the Applicant shall investigate and report on the matter promptly. UK Biobank may require, if reasonably necessary (and subject to a dialogue with the Applicant), the Applicant to: 14.10.1 to audit the Third-Party Processor; and / or 14.10.2 terminate the agreement with the Third-Party Processor.
* 対応するEGAの条文はありません
* 対応するNIHの条文はありません

***

### 15. Force majeure
### 15.1 If a party is prevented from, hindered or delayed in performing any of its obligations under this MTA by reason of a Force Majeure Event, such party shall promptly notify the other of the date of its commencement and the effects of the Force Majeure Event on its ability to perform its obligations under this MTA. If mutually agreed by the parties, then the obligations of the party so affected shall thereupon be suspended for so long as the Force Majeure Event may continue.
* 対応するEGAの条文はありません
* 対応するNIHの条文
    * **10. Miscellaneous**
    * 比較結果：部分一致
    * 判断理由：NIHの条文10は、不可抗力を含む一般的な雑則を扱っているが、具体的な内容についてはUKBBほど詳細ではないため、部分的な一致と判断しました。

### 15.2 The party affected by a Force Majeure Event shall not be liable for any failure to perform or delay in performing such of its obligations as are prevented, hindered or delayed by the Force Majeure Event provided that such party shall use every reasonable effort to minimise the effects thereof and shall resume performance as soon as possible after the removal of such Force Majeure Event. If the period of non-performance exceeds 90 days from the start of the Force Majeure Event then the non-affected party shall have the option, by written notice to the other party, to terminate this MTA by giving thirty (30) days’ written notice to the other party.
* 対応するEGAの条文はありません
* 対応するNIHの条文
    * **10. Miscellaneous**
    * 比較結果：部分一致
    * 判断理由：NIHの条文10は、不可抗力を含む一般的な雑則を扱っているが、不可抗力による責任の免除や契約終了の具体的な条件についてはUKBBほど詳細ではないため、部分的な一致と判断しました。

### 15.3 The provisions of this clause 15 shall not affect any other right which any party may have to terminate this MTA.
* 対応するEGAの条文はありません
* 対応するNIHの条文
    * **10. Miscellaneous**
    * 比較結果：部分一致
    * 判断理由：NIHの条文10は、不可抗力を含む一般的な雑則を扱っているが、契約終了に関する他の権利との関係について具体的な記載がないため、部分的な一致と判断しました。

***

### 条文番号の対応表

| UKBBの条文番号 | EGAの条文番号 | NIHの条文番号 |
|---|---|---|
| 13.1 | なし | なし |
| 13.2 | なし | なし |
| 13.3 | なし | なし |
| 14.1 | なし | なし |
| 14.2 | なし | なし |
| 14.3 | なし | なし |
| 14.4 | なし | なし |
| 14.5 | なし | なし |
| 14.6 | なし | なし |
| 14.7 | なし | なし |
| 14.8 | なし | なし |
| 14.9 | なし | なし |
| 14.10 | なし | なし |
| 15.1 | なし | 10 |
| 15.2 | なし | 10 |
| 15.3 | なし | 10 |